Nexalin Technology NXL
NASDAQ NXL
$0.33 +0.00 (+0.03%)
At close: Aug 20, 2026 · 12:43 PM UTC

Nexalin Technology (NXL) Total Debt (2021)

Nexalin Technology (NXL) posted quarterly Total Debt of $60116.0 for Q4 2021.

Nexalin Technology (NXL) Total Debt (2021) Analysis & Trends

Nexalin Technology's Total Debt history runs 1 years deep, the most recent figure standing at $60116.0 for Q4 2021.

  • In Q4 2021, Total Debt changed N/A year-over-year to $60116.0; the TTM figure through Dec 2021 stood at $60116.0 (changed N/A YoY), while the FY2021 annual figure was $60116.0, changed N/A from the prior year.
  • Total Debt for Q4 2021 stood at $60116.0.
  • The five-year high for Total Debt was $60116.0 in Q4 2021, with the low at $60116.0 in Q4 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Abbott Laboratories 199.24 Bn 193.64 Bn 7.27 Bn 32.61 Bn
2 Stryker 128.63 Bn 125.15 Bn 4.50 Bn 14.94 Bn
3 Medtronic 119.19 Bn 109.97 Bn 6.41 Bn 27.96 Bn
4 Boston Scientific 73.51 Bn 72.97 Bn 3.85 Bn 12.62 Bn
5 Edwards Lifesciences 52.11 Bn 47.85 Bn 1.35 Bn 598.70 Mn
6 Dexcom 34.64 Bn 32.70 Bn 830.00 Mn -
7 GE HealthCare Technologies 34.01 Bn 31.90 Bn 2.18 Bn 10.10 Bn
8 Koninklijke Philips 26.40 Bn 23.08 Bn 4.55 Bn 8.68 Bn
9 Steris 23.14 Bn 22.65 Bn 684.20 Mn 1.89 Bn
10 Nexalin Technology 6.98 Mn 5.97 Mn 8,897.00 -

Historic Data

Download Data
DateValue
Dec 31, 2021 60,116.00